Breast Cancer Consortium
Breast Cancer
UnknownActive
Key Facts
About Criterium
Criterium is a long-established, privately-held CRO that has carved out a specialized niche in oncology clinical research through its innovative Oncology Consortia model. The company combines hands-on operational expertise with technology solutions like interactive voice/web response (IVR/IWR) and ePRO to manage complex trials efficiently. Its core strategy involves forming disease-specific consortia with top-tier universities and cancer centers, enabling rapid patient recruitment and high-quality data generation for pharmaceutical and biotech sponsors. While primarily a service provider, its deep integration into therapeutic development gives it significant insight into the oncology pipeline landscape.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Antifibrotic Therapy Program | MeCo Diagnostics | Pre-clinical |
| inPROBE for HER2 | SDS Optic | Clinical Investigation |
| ACT‑BC1 | Anthrocell | Preclinical |
| APA-1000 Breast Thermotherapy System | Medifocus | Phase III |
| Early‑Detection Breast Cancer Screening | Karkinos Healthcare | Market |
| Unnamed Breast Cancer Program | Click Therapeutics | Pilot/Phase 2 |
| Lerociclib (Lerocliclib) | Chemogenics BioPharma | Phase 3 |
| AT-017 | Asieris Pharmaceuticals | Not Specified |
| CDK2 inhibitor | Acellera | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Maveropepimut-S (MVP-S) | BioVaxys | Clinical Evaluation |
| Cannabics® BRST-33 | CNBX Pharmaceuticals | Discovery |